Results 111 to 120 of about 4,786 (145)

Ganciclovir

2018
Ganciclovir is synthetic nucleoside analog of guanine closely related to acyclovir but has greater activity against cytomegalovirus. This comprehensive profile on ganciclovir starts with a description of the drug: nomenclature, formulae, chemical structure, elemental composition, and appearance. The uses and application of the drug are explained.
Abdullah A, Al-Badr, Tariq D S, Ajarim
openaire   +2 more sources

Ganciclovir treatment in Ménétrier's disease

Acta Paediatrica, 2003
A 2‐y‐old girl with severe edema, oliguria and hypoalbuminemia caused by protein‐losing gastritis was diagnosed with cytomegalovirus‐associated Ménétrier's disease. After almost two weeks, during which the patient required repeated albumin transfusions, she was treated with intravenous ganciclovir.
M Feinmesser, Yaron Finkelstein, Ben-Zion Garty, J Balter, Vered Hoffer   +4 more
openaire   +3 more sources

Seizures Associated With Ganciclovir Therapy

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1992
A 32‐year‐old man diagnosed with acquired immunodeficiency syndrome and a disseminated cytomegalovirus infection experienced seizures associated with the administration of ganciclovir. Seizures began 1 month after initiation of therapy and worsened with increasing dosages.
Lisa L. Dever, Maura K. Roush, Terri L. Barton   +2 more
openaire   +2 more sources

Solubility and Micronization of Ganciclovir

Advanced Materials Research, 2011
Ganciclovir (GCV) is only slightly soluble in water and hence oral GCV gives low absolute bioavailability. Liquid precipitation is an effective way to prepare micro-sized drug particles. The solubility of GCV in several solvents or in aqueous solution at different pH values was determined.
Zhong Li Guo, Su Na Lin, Feng Xiang Tang, Yun Zhang   +3 more
openaire   +2 more sources

Ganciclovir for the treatment of anterior uveitis

Graefe's Archive for Clinical and Experimental Ophthalmology, 2000
Ganciclovir, administered systemically or intraocularly, is effective in controlling cytomegalovirus (CMV) retinitis in immunocompromised patients. The efficacy of therapy with this antiviral substance was investigated in an immunocompetent patient with CMV uveitis causing secondary glaucoma.To identify the presence of an intraocular viral infection ...
S Aisenbrey, K. Ulrich Bartz-Schmidt, Günter K. Krieglstein, Stephan Bamborschke, Holger Mietz   +4 more
openaire   +3 more sources

Evaluation of Ganciclovir for Cytomegalovirus Disease

DICP, 1989
Cytomegalovirus (CMV) infections are a common cause of morbidity and mortality in immunosuppressed patients. Ganciclovir is an acyclic deoxyguanosine analog structurally similar to acyclovir but with superior activity against CMV. The median ganciclovir concentration required to inhibit viral replication by 50 percent is 2.15 μmol versus 72 μmol for ...
Courtney V. Fletcher, Henry H. Balfour
openaire   +3 more sources

Intravitreal Sustained-Release Ganciclovir

Archives of Ophthalmology, 1992
Current treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome involves frequent intravenous administration of sodium ganciclovir that often results in unacceptable side effects. We have developed devices that release ganciclovir at rates of 2 micrograms/h and 5 micrograms/h in vitro. When implanted into the vitreous
Paul Ashton, Joel D. Brown, Larry B. Baldwin, Peter G. Glavinos, Jack L. Hollins, Thomas J. Smith, P. Andrew Pearson, Kenneth A. Goins, David L. Blandford, Elmar T. Schmeisser   +9 more
openaire   +3 more sources

Treatment of Rasmussen's syndrome with ganciclovir

Neurology, 1996
Since cytomegalovirus (CMV) has been implicated in the pathogenesis of Rasmussen's syndrome, we treated four patients with ganciclovir, a potent anti-CMV drug. A 7-year-old girl with seizures escalating to 60/day over 3 months despite triple antiepileptic drug therapy became seizure-free 5 days after initiation of treatment with no recurrence at 1.5 ...
Simon Levin, Warren T. Blume, Richard S. McLachlan   +2 more
openaire   +3 more sources

Treatment of Cytomegalovirus Retinopathy with Ganciclovir

Ophthalmology, 1987
Ganciclovir is an experimental antiviral drug with activity against human cytomegalovirus (CMV). Forty patients with acquired immune deficiency syndrome (AIDS) and CMV retinopathy were treated with ganciclovir on a compassionate protocol basis. Initial treatment doses ranged from 5.0 to 14.0 mg/kg/day for 9 to 26 days.
Lisa M. Frenkel, Gary N. Holland, Gary N. Holland, James D. Cherry, Yvonne J. Bryson, Richard E. Champlin, Allan E. Kreiger, Allan E. Kreiger, Peter R. Wolfe, Michael S. Gottlieb, David J. Hardy, Winston G. Ho, Yossi Sidikaro, Yossi Sidikaro, Robert E. Winters, Drew J. Winston, Michael J. Sakamoto, Michael J. Sakamoto   +17 more
openaire   +3 more sources

Acyclovir- and Ganciclovir-Induced Neurotoxicity

Annals of Pharmacotherapy, 1998
With increasing use of acyclovir and ganciclovir, primarily due to the increased number of AIDS and transplant patients, further cases of neurologic toxicity will undoubtedly be encountered. Discontinuation or dosage reduction of acyclovir and ganciclovir is necessary to manage neurologic toxicity that is directly attributed to either agent.
Rodney J Franey, Michael E. Ernst
openaire   +2 more sources